Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer
Diletta Di Mitri,
Michela Mirenda,
Jelena Vasilevska,
Arianna Calcinotto,
Nicolas Delaleu,
Ajinkya Revandkar,
Veronica Gil,
Gunther Boysen,
Marco Losa,
Simone Mosole,
Emiliano Pasquini,
Rocco D’Antuono,
Michela Masetti,
Elena Zagato,
Giovanna Chiorino,
Paola Ostano,
Andrea Rinaldi,
Letizia Gnetti,
Mariona Graupera,
Ana Raquel Martins Figueiredo Fonseca,
Ricardo Pereira Mestre,
David Waugh,
Simon Barry,
Johann De Bono,
Andrea Alimonti
Affiliations
Diletta Di Mitri
Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Via A. Manzoni 113, 20089 Rozzano, Milan, Italy
Michela Mirenda
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Jelena Vasilevska
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Arianna Calcinotto
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Nicolas Delaleu
Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Swiss Institute of Bioinformatics, Lausanne, Switzerland; 2C SysBioMed, 6646 Contra, Switzerland
Ajinkya Revandkar
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Veronica Gil
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
Gunther Boysen
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
Marco Losa
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Simone Mosole
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Emiliano Pasquini
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Rocco D’Antuono
Institute for Research in Biomedicine (IRB), 6500 Bellinzona, Switzerland
Michela Masetti
Istituto Clinico Humanitas, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Via A. Manzoni 113, 20089 Rozzano, Milan, Italy
Elena Zagato
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Giovanna Chiorino
Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Via Malta, 3, 13900 Biella, Italy
Paola Ostano
Cancer Genomics Lab, Fondazione Edo ed Elvo Tempia, Via Malta, 3, 13900 Biella, Italy
Andrea Rinaldi
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland
Letizia Gnetti
Pathology Unit, University Hospital of Parma, 43126 Parma, Italy
Mariona Graupera
Vascular Signalling Laboratory, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; Program Against Cancer Therapeutic Resistance (ProCURE), Barcelona, Spain; CIBERONC, Madrid, Spain
Ana Raquel Martins Figueiredo Fonseca
Vascular Signalling Laboratory, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, Spain; Program Against Cancer Therapeutic Resistance (ProCURE), Barcelona, Spain; CIBERONC, Madrid, Spain
Ricardo Pereira Mestre
Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
David Waugh
Movember Centre of Excellence, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK
Simon Barry
IMED Oncology AstraZeneca, Li KaShing Centre, Cambridge, UK
Johann De Bono
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK
Andrea Alimonti
Institute of Oncology Research (IOR), 6500 Bellinzona, Switzerland; Faculty of Medicine, Università della Svizzera Italiana, 1011 Lugano, Switzerland; Department of Medicine, University of Padua, 35131 Padua, Italy; Medical Oncology, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland; Corresponding author
Summary: Tumor-associated macrophages (TAMs) represent a major component of the tumor microenvironment supporting tumorigenesis. TAMs re-education has been proposed as a strategy to promote tumor inhibition. However, whether this approach may work in prostate cancer is unknown. Here we find that Pten-null prostate tumors are strongly infiltrated by TAMs expressing C-X-C chemokine receptor type 2 (CXCR2), and activation of this receptor through CXCL2 polarizes macrophages toward an anti-inflammatory phenotype. Notably, pharmacological blockade of CXCR2 receptor by a selective antagonist promoted the re-education of TAMs toward a pro-inflammatory phenotype. Strikingly, CXCR2 knockout monocytes infused in Ptenpc−/−; Trp53pc−/− mice differentiated in tumor necrosis factor alpha (TNF-α)-releasing pro-inflammatory macrophages, leading to senescence and tumor inhibition. Mechanistically, PTEN-deficient tumor cells are vulnerable to TNF-α-induced senescence, because of an increase of TNFR1. Our results identify TAMs as targets in prostate cancer and describe a therapeutic strategy based on CXCR2 blockade to harness anti-tumorigenic potential of macrophages against this disease. : Di Mitri et al. show that CXCR2 blockade in prostate cancer triggers TAMs re-education, leading to tumor inhibition. CXCR2-KO monocytes infused in Ptenpc−/−; Trp53pc−/− tumor-bearing mice differentiate into TNFα-releasing pro-inflammatory macrophages that induce senescence in tumor cells. PTEN-null tumors display higher sensitivity to TNF-α-induced senescence because of TNFR1 upregulation. Keywords: prostate cancer, tumor immunology, immunomodulation, immune response to cancer, tumor associated macrophages